Clinical Trial

A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 24, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary pharmacodynamic characteristics of GR2301 injection in healthy adult subjects in China.The GR2301 injection dosage will be gradually increased. All healthy subjects will receive a single subcutaneous injection. Following administration, subjects will be followed for at least 16 weeks ± 7 days.
Trial Details
NCT Number NCT07190716
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions Single Ascending Dose, Healthy Subjects
Enrollment 36 participants
Start Date 2025-10-10
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-24